
Experimental drug lepodisiran cuts heart disease risk factor by 94%
A single dose of an experimental drug has been found to reduce the risk of genetic heart disease by 94%. Lepodisiran, an experimental drug developed by Eli Lilly, has shown promising results in reducing levels of lipoprotein(a), or Lp(a), a genetically …